Keele, UK, 12th September 2006 - UK based Cobra Biomanufacturing Plc (AIM:CBF) announced today an agreement with the Italian Telethon Foundation to manufacture plasmids for two innovative gene therapy trials. The materials produced by Cobra are planned to be used in clinical trials for the treatment of the inherited disorders Metachromic Leukodystrophy and Wiskott-Aldrich Syndrome.
